|
|
|
Insider
Information: |
Secora Michael |
Relationship: |
Chief Financial Officer |
City: |
Salt Lake City |
State: |
UT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
1,402,131 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$10,053,279 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
1,402,131 |
|
|
Total
Value |
$10,053,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
|
|
Stock
price went down : |
|
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Recursion Pharmaceuticals, Inc. |
RXRX |
Chief Financial Officer |
2024-09-11 |
1,402,131 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
82 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
182,849 |
1,163,863 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-13 |
4 |
AS |
$9.86 |
$246,560 |
D/D |
(25,000) |
1,173,851 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-13 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,198,851 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-14 |
4 |
AS |
$10.43 |
$261,425 |
D/D |
(25,000) |
1,186,351 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-14 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,211,351 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-15 |
4 |
D |
$12.43 |
$89,148 |
D/D |
(7,172) |
1,179,179 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-03-12 |
4 |
AS |
$10.46 |
$261,375 |
D/D |
(25,000) |
1,191,679 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-03-12 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,216,679 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-03-13 |
4 |
AS |
$11.03 |
$275,815 |
D/D |
(25,000) |
1,204,179 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-03-13 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,229,179 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-04-16 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,241,679 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-04-16 |
4 |
AS |
$7.67 |
$191,658 |
D/D |
(25,000) |
1,216,679 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-04-17 |
4 |
AS |
$7.58 |
$175,349 |
D/D |
(23,124) |
1,231,055 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-04-17 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,254,179 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-05-15 |
4 |
D |
$10.01 |
$119,740 |
D/D |
(11,962) |
1,219,093 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-06-13 |
4 |
AS |
$9.32 |
$139,799 |
D/D |
(15,000) |
1,243,468 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-06-13 |
4 |
OE |
$2.22 |
$87,413 |
D/D |
39,375 |
1,258,468 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-06-14 |
4 |
AS |
$9.27 |
$139,082 |
D/D |
(15,000) |
1,267,843 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-06-14 |
4 |
OE |
$2.22 |
$87,413 |
D/D |
39,375 |
1,282,843 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-07-09 |
4 |
AS |
$7.32 |
$109,778 |
D/D |
(15,000) |
1,292,218 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-07-09 |
4 |
OE |
$2.22 |
$87,413 |
D/D |
39,375 |
1,307,218 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-07-10 |
4 |
OE |
$2.22 |
$87,413 |
D/D |
39,375 |
1,331,593 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-07-10 |
4 |
AS |
$7.24 |
$108,576 |
D/D |
(15,000) |
1,316,593 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-08-13 |
4 |
AS |
$6.35 |
$95,183 |
D/D |
(15,000) |
1,340,968 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-08-13 |
4 |
OE |
$2.22 |
$87,413 |
D/D |
39,375 |
1,355,968 |
0 |
- |
|
82 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|